Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Lucid Diagnostics (NASDAQ:LUCD) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $2.50 price target on the stock.

A number of other equities research analysts also recently weighed in on LUCD. Canaccord Genuity Group raised Lucid Diagnostics to a “strong-buy” rating in a report on Tuesday, August 13th. Ascendiant Capital Markets reduced their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research note on Tuesday, September 10th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $3.69.

Lucid Diagnostics Trading Down 2.3 %

NASDAQ LUCD opened at $0.99 on Thursday. The firm’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $0.85. The firm has a market capitalization of $58.56 million, a price-to-earnings ratio of -0.87 and a beta of 1.41. Lucid Diagnostics has a 1 year low of $0.63 and a 1 year high of $1.58.

Hedge Funds Weigh In On Lucid Diagnostics

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC raised its holdings in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the quarter. Virtu Financial LLC owned approximately 0.07% of Lucid Diagnostics worth $28,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.